(Q36609417)

15 August 2017

1 reference

title

Allogeneic stem cell transplantation as treatment for myelofibrosis (English)

1 reference

15 August 2017

Papageorgiou SG

1

1 reference

15 August 2017

Castleton A

series ordinal

2

1 reference

15 August 2017

Bloor A

series ordinal

3

1 reference

15 August 2017

Kottaridis PD

series ordinal

4

1 reference

15 August 2017

language of work or name

English

0 references

publication date

2 October 2006

1 reference

Bone Marrow Transplantation

15 August 2017

1 reference

15 August 2017

38

1 reference

15 August 2017

11

1 reference

15 August 2017

721-727

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1705516

15 August 2017

0 references

cites work

Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705516

Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705516

Identification of 'short-lived' and 'long-lived' patients at presentation of idiopathic myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705516

Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705516

Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705516

A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705516

Surgical and radiotherapeutic approaches for myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705516

Allogeneic bone marrow transplantation for primary myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705516

Allogeneic marrow transplantation for myeloproliferative disorders other than chronic myelogenous leukemia: review of forty cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705516

Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705516

Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705516

Dose-reduced conditioning regimen followed by allogeneic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705516

FLAG chemotherapy followed by allogeneic stem cell transplant using nonmyeloablative conditioning induces regression of myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705516

Long-term remission of myelofibrosis following nonmyeloablative allogeneic peripheral blood progenitor cell transplantation in older age: the Scripps Clinic experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705516

Hematopoietic stem cell transplantation for myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705516

Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705516

A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705516

Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705516

Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705516

Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705516

Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705516

Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705516

Complete remission of idiopathic myelofibrosis following donor lymphocyte infusion after failure of allogeneic transplantation: demonstration of a graft-versus-myelofibrosis effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705516

Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705516

7 January 2021

Myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705516

7 January 2021

Long term treatment of myeloproliferative disease with interferon-alpha-2b: feasibility and efficacy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705516

7 January 2021

Allogeneic bone marrow transplantation for primary myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705516

7 January 2021

Allogeneic marrow transplantation for primary myelofibrosis and myelofibrosis secondary to polycythaemia vera or essential thrombocytosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705516

7 January 2021

Allogeneic bone marrow transplantation for agnogenic myeloid metaplasia. French Society of Bone Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705516

7 January 2021

Allogeneic hematopoietic stem cell transplantation for myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705516

7 January 2021

Stem cell transplantation for myelofibrosis: a report from two Canadian centers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705516

7 January 2021

Outcome of allogeneic stem cell transplantation in patients with myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705516

7 January 2021

Myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705516

7 January 2021

Induction of remission after donor leucocyte infusion for the treatment of relapsed chronic idiopathic myelofibrosis following allogeneic transplantation: evidence for a 'graft vs. myelofibrosis' effect

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705516

7 January 2021

Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705516

7 January 2021

Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia: a simple CBC-based scoring system

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705516

7 January 2021

Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705516

7 January 2021

High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705516

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1705516

1 reference

15 August 2017

1 reference